As of today (2024-04-19), Repligen's share price is $159.12.
Repligen's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $2.01. Hence, Repligen's Price-to-Operating-Cash-Flow Ratio for today is 79.09.
The historical rank and industry rank for Repligen's Price-to-Operating-Cash-Flow or its related term are showing as below:
RGEN'
s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 12.45 Med: 78.59 Max: 328.3
Current: 79.07
During the past 13 years, Repligen's highest Price-to-Operating-Cash-Flow Ratio was 328.30. The lowest was 12.45. And the median was 78.59.
Repligen's Cash Flow from Operations per share for the
three
months ended in Dec. 2023 was $0.52.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $2.01.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Repligen was -32.50% per year.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 20.30% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 26.00% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 20.40% per year.
During the past 13 years, Repligen's highest 3-Year average Operating Cash Flow per Share Growth Rate was 143.40% per year. The lowest was -60.60% per year. And the median was 17.20% per year.
Repligen Price-to-Operating-Cash-Flow Historical Data
The historical data trend for Repligen's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
Repligen Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Price-to-Operating-Cash-Flow |
|
|
|
|
|
|
67.72 |
164.91 |
127.45 |
56.53 |
88.97 |
|
Repligen Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Price-to-Operating-Cash-Flow |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
56.53 |
59.94 |
54.22 |
61.73 |
88.97 |
Competitive Comparison
For the Medical Instruments & Supplies subindustry, Repligen's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Repligen Price-to-Operating-Cash-Flow Distribution
For the Medical Devices & Instruments industry and Healthcare sector, Repligen's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Repligen's Price-to-Operating-Cash-Flow falls into.
Repligen Price-to-Operating-Cash-Flow Calculation
Repligen's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 159.12 | / | 2.012 |
| = | 79.09 |
Repligen's Share Price of today is $159.12.
Repligen's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Repligen (Repligen) Business Description
Traded in Other Exchanges
Address
41 Seyon Street, Building 1, Suite 100, Waltham, MA, USA, 02453
Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America.
Executives
| Christine Gebski |
officer: See Remarks |
C/O REPLIGEN CORPORATION, 41 SYON ST. BLDG. 1, SUITE 100, WALTHAM MA 02453 |
| Olivier Loeillot |
officer: President and CCO |
C/O REPLIGEN CORPORATION, 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02453 |
| Jason K Garland |
officer: CFO |
10000 WEHRLE DRIVE, CLARENCE NY 14031 |
| Karen A Dawes |
director |
579 BELLEVUE AVE, NEWPORT RI 02840 |
| Martin D Madaus |
director |
290 CONCORD ROAD, BILLERICA MA 01821 |
| Jon Snodgres |
officer: CFO |
REPLIGEN CORPORATION, 41 SEYON STREET, BUILDING #1, SUITE 100, WALTHAM MA 02435 |
| Anthony Hunt |
director, officer: Chief Executive Officer |
41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02452 |
| Ralf Kuriyel |
officer: Senior VP, R&D |
41 SEYON ST, BLDG 1, STE. 100, WALTHAM MA 02452 |
| James Bylund |
officer: SVP, Global Operations & IT |
C/O REPLIGEN CORPORATION, 41 SYON ST. BLDG. SUITE 100, WALTHAM MA 02453 |
| Konstantin Konstantinov |
director |
C/O CODIAK BIOSCIENCES, INC., 500 TECHNOLOGY SQUARE, 9TH FLOOR, CAMBRIDGE MA 02139 |
| Manner Carrie Eglinton |
director |
C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094 |
| Ryan Thomas F Jr |
director |
|
| Nicolas Barthelemy |
director |
1750 BELLA LAGUNA CT, ENCINITAS CA 92024 |
| John Cox |
director |
C/O BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451 |
| Rohin Mhatre |
director |
C/O REPLIGEN CORP., 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02453 |
Repligen (Repligen) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RGEN has been successfully added to your